Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers

Phase 1 Completed 10 enrolled Pfizer

Non-randomizedSingle-groupOpen-label

Summary

This study will evaluate the safety, tolerability, and pharmacokinetics of PF-04236921 administered as a single subcutaneous dose in healthy volunteers.

Timeline

Start: 2010-05
Primary completion: 2010-10
Completion: 2010-10

Publications

Li C, Shoji S, Beebe J. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. Br J Clin Pharmacol. 2018 Sep;84(9):2059-2074. doi: 10.1111/bcp.13641. Epub 2018 Jun 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PACIBEKITUG	Monoclonal antibody	—	Subcutaneous

Indications

No indication recorded.